Overview

Detailed Summary

Vilin Bio Med Limited is primarily engaged in manufacturing pharmaceutical products, specializing in both Beta-Lactam and Non-Beta-Lactam medicines.
The company boasts a robust portfolio of over 1000 drug approvals across diabetic, neurological, and cardiovascular therapeutic areas.
Vilin Bio Med has a state-of-the-art manufacturing facility and R&D foundation in Roorkee, enhancing its product innovation capabilities.
The company's recent IPO in 2023 raised Rs 12 Crore, marking a significant step for its financial strategy and growth plans.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 73 Cr
Volatility: Low Risk
P/E Ratio: 37.7
Industry P/E: 34.1
PEG Ratio: 0.4
P/B Ratio: 2.6
52W High: 54.40
52W Low: 18.95

Sales CAGR

1Y: -6.27%
3Y: 9.71%
5Y: -2.51%
10Y: —

Profit CAGR

1Y: 37.50%
3Y: 88.07%
5Y: 6.62%
10Y: —

ROE

TTM: 6.80%
3Y: 2.88%
5Y: 2.50%
10Y: —

ROCE

TTM: 10.18%
3Y: 7.99%
5Y: 7.76%
10Y: —

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ZENITHDRUG		43.90	78 Cr	8.35	1.25	0.00	15.41	18.92	6.93
PHRMASI		104.47	75 Cr	4.27	4.21	0.00	8.93	11.29	58.48
VILINBIO		47.00	73 Cr	37.73	2.57	0.00	6.80	10.18	5.52
BIBCL		17.01	73 Cr	-4.02	0.00	0.00	-22.95	-11.16	-9.61
ONYX		39.20	73 Cr	-345.38	1.31	0.00	-0.39	1.12	-0.22
BACPHAR		43.67	70 Cr	51.97	2.76	0.00	6.27	3.99	4.89
VINEETLAB		33.22	67 Cr	-6.60	1.52	0.00	-117.41	-22.41	-11.20
Median: 7 Co.	—	43.67	73 Cr	4.27	1.52	0.00	6.27	3.99	4.89

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Half Yearly Results (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026
Sales	4.95	4.10	8.21	7.65	8.16	4.49	10	9.66	33
Expenses	4.57	3.00	6.75	6.25	8.74	4.08	9.95	9.33	30
Interest	0.25	0.32	0.33	0.38	0.41	0.41	0.44	0.07	0.00
Operating Profit	0.38	1.10	1.46	1.40	-0.58	0.41	0.37	0.33	2.86
OPM %	7.68	26.83	17.78	18.30	-7.11	9.13	3.59	3.42	8.77
Other Income	0.00	0.00	0.02	0.11	0.22	0.22	0.25	0.00	0.00
Depreciation	0.11	0.08	0.08	0.08	0.05	0.07	0.03	0.07	0.21
Profit Before Tax	0.03	0.70	1.08	1.04	-0.82	0.15	0.15	0.19	2.65
Tax %	33.33	21.43	36.11	25.96	25.61	20.00	33.33	21.05	32.83
Net Profit	0.02	0.55	0.69	0.77	-0.61	0.12	0.10	0.15	1.78
EPS in Rs	—	—	—	—	—	—	—	—	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	17	12	11	12	16	15
Expenses	16	11	10	9.74	15	14
Operating Profit	0.90	0.86	0.77	2.57	0.82	0.79
OPM %	5.35	7.31	6.83	20.90	5.17	5.31
Other Income	0.01	0.00	0.00	0.02	0.32	0.47
Interest	0.41	0.44	0.51	0.65	0.79	0.85
Depreciation	0.31	0.26	0.22	0.17	0.13	0.10
Profit Before Tax	0.19	0.16	0.04	1.78	0.23	0.31
Tax %	16.31	24.71	24.83	30.12	27.89	26.91
Net Profit	0.16	0.12	0.03	1.25	0.16	0.22
EPS in Rs	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	3.30	3.30	3.30	9.95	14	14
Reserves	3.94	4.06	4.10	0.73	8.89	9.11
Borrowings	4.53	5.52	5.30	4.93	6.83	2.57
Other Liabilities	2.23	1.01	0.86	2.07	2.73	2.09
Total Liabilities	14	14	14	18	32	28
Fixed Assets	2.13	1.87	1.65	1.51	1.38	1.28
CWIP	0.00	0.00	0.00	0.00	0.00	1.57
Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	12	12	12	16	31	25
Total Assets	14	14	14	18	32	28

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-1.46	-1.00	0.21	-1.66	-5.30	0.22
Cash from Investing Activity	-0.02	0.00	0.00	-0.03	0.32	-1.11
Cash from Financing Activity	1.51	0.98	-0.22	1.68	11	-5.10
Net Cash Flow	0.03	-0.02	-0.01	-0.00	6.01	-5.99

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	May 2026
Promoters	90.45%	64.52%	64.52%	64.09%	63.89%	63.89%	63.89%	63.65%	59.57%	56.65%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	9.55%	35.48%	35.48%	35.91%	36.11%	36.11%	36.11%	36.35%	40.43%	43.35%
Total Shareholders	21	659	585	581	551	492	476	462	421	400

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

CFO Resignation

2 days ago

Vilin Bio Med CFO Resignation

Vilin Bio Med informed the exchange that CFO Mr. Avula Hariprasad resigned effective close of business on June 11, 2026, citing pre-occupation and personal reasons; Reg.30 disclosure filed.

CFO Resignation

2 days ago

Resignation of CFO Avula Hariprasad

Vilin Bio Med informed the Exchange that Mr. Avula Hariprasad has resigned as Chief Financial Officer effective close of business on June 11, 2026, citing pre‑occupations/personal commitments.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Vilin Bio Med Ltd

Vilin Bio Med Ltd (VILINBIO) is currently trading at 47.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vilin Bio Med Limited is primarily engaged in manufacturing pharmaceutical products, specializing in both Beta-Lactam and Non-Beta-Lactam medicines. The company boasts a robust portfolio of over 1000 drug approvals across diabetic, neurological, and cardiovascular therapeutic areas. Vilin Bio Med has a state-of-the-art manufacturing facility and R&D foundation in Roorkee, enhancing its product innovation capabilities. The company's recent IPO in 2023 raised Rs 12 Crore, marking a significant step for its financial strategy and growth plans.

Over the past 52 weeks, Vilin Bio Med Ltd has traded between a low of ₹18.95 and a high of ₹54.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vilin Bio Med Ltd has a market capitalization of approximately 72.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vilin Bio Med Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 72.82 Cr, Vilin Bio Med Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vilin Bio Med Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vilin Bio Med Ltd is 37.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vilin Bio Med Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison